Moderna Earnings: What To Look For From MRNA

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations significantly.

Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Moderna’s revenue to decline 58.7% year on year to $769.6 million, a reversal from the 1.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$2.16 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Moderna has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 31.6% on average.

Looking at Moderna’s peers in the therapeutics segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Amgen delivered year-on-year revenue growth of 12.4%, beating analysts’ expectations by 6.7%, and Gilead Sciences reported revenues up 3%, topping estimates by 3.7%. Gilead Sciences traded up 1.2% following the results.

Read our full analysis of Amgen’s results here and Gilead Sciences’s results here.

Investors in the therapeutics segment have had steady hands going into earnings, with share prices flat over the last month. Moderna is down 14.1% during the same time and is heading into earnings with an average analyst price target of $40.30 (compared to the current share price of $23.67).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.